Payment overview · 2025
General Payments
$349.08
9 reported records · 4 companies
Healthcare provider profile · identity verified
Ian S Elliot, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · TOLEDO, OH · NPI 1649277328
Verified facts
What the public records show
CMS Open Payments records show Ian S Elliot, MD received $349.08 in general payments during 2025 across 9 reported records.
Tandem Diabetes Care, Inc. accounted for 58.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $203.27 | 58.2% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $115.00 | 32.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.63 | 4.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.18 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $175.00 | 1 |
| Food and Beverage | $174.08 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $203.27 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $115.00 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1671 | 435 |
| Methimazole | Methimazole | 305 | 75 |
| Synthroid | Levothyroxine Sodium | 296 | 78 |
| Metformin Hcl | Metformin Hcl | 148 | 44 |
| Ozempic | Semaglutide | 120 | 24 |
| Atorvastatin Calcium | Atorvastatin Calcium | 106 | 35 |
| Hydrocortisone | Hydrocortisone | 104 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 103 | 34 |
| Metformin Hcl Er | Metformin Hcl | 103 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 25 |
| Alendronate Sodium | Alendronate Sodium | 84 | 20 |
| Simvastatin | Simvastatin | 81 | 22 |
| Atenolol | Atenolol | 77 | 22 |
| Losartan Potassium | Losartan Potassium | 75 | 19 |
| Trulicity | Dulaglutide | 74 | 17 |
| Lisinopril | Lisinopril | 73 | 22 |
| Novolog Flexpen | Insulin Aspart | 63 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 59 | 24 |
| Potassium Chloride | Potassium Chloride | 54 | suppressed |
| Testosterone | Testosterone | 54 | 16 |
| Gabapentin | Gabapentin | 52 | 13 |
| Glimepiride | Glimepiride | 50 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 42 | suppressed |
| Allopurinol | Allopurinol | 41 | suppressed |
| Humalog | Insulin Lispro | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Cabergoline | Cabergoline | 33 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Prednisone | Prednisone | 33 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 29 | suppressed |
| Furosemide | Furosemide | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Forteo | Teriparatide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 18 | suppressed |
| Liraglutide | Liraglutide | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Genotropin | Somatropin | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Victoza 3-Pak | Liraglutide | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Humatrope | Somatropin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $349.08 · 9 records | Tandem Diabetes Care, Inc. | Korlym, MINIMED 780G, TEPEZZA, t:slim X2 Insulin Pump with Control-IQ | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error